C3 and breast cancer: A study by Huh et al.18on the late intervention of 2‐ME, which correlates with the early‐stage BC group in this study, found that there was a 60% decrease in tumour volume in 2‐ME‐treated C3(1)/Tag transgenic mice compared with controls, and suggested that a high dose of 150 mg/kg can decrease tumour volume and inhibit angiogenesis.